Clinical trial
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related…
NCT00144703 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00144703 |
|---|---|
| Title | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation |
| Official title | Open Label Phase II Trial of Sirolimus in Combination With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hematologic Malignancies, Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Disease |
| Intervention type | Drug |
| Interventions | Sirolimus, Tacrolimus |
| Enrollment | 55 |
| Start date | Jul 1, 2002 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Sep 5, 2005 |
| Last update posted | Jan 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: